Clinical Trial: Vitamin C Infusion for Severe 2019-nCoV Infected Pneumonia

Brief Summary:

2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI.

Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections.

We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.

Study Type  :Interventional  (Clinical Trial)
Estimated Enrollment  :140 participants
Intervention Model:Parallel Assignment
Masking:Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:Treatment
Official Title:Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial
Estimated Study Start Date  :February 10, 2020
Estimated Primary Completion Date  :September 30, 2020
Estimated Study Completion Date  :September 30, 2020

Worth keeping an eye on.   Positive results may be ignored by the MSM.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.